{
    "clinical_study": {
        "@rank": "26906", 
        "arm_group": [
            {
                "arm_group_label": "Interventional", 
                "arm_group_type": "Experimental", 
                "description": "Interventional group: activated autologous NK cell treatment"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "No Intervention", 
                "description": "Control group: BSC"
            }
        ], 
        "brief_summary": {
            "textblock": "Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients\n      with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT)"
        }, 
        "brief_title": "Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "NSCLC Stage IIIA/B", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with non-small cell lung carcinoma (NSCLC) in stage III A and III B showing at\n      least stable disease after RCTx will be enrolled into the clinical trial. The aim of the\n      study is to show the efficacy of an adjuvant treatment with Hsp70-peptide TKD/IL-2\n      activated, autologous NK cells following completion of standard radiochemotherapy\n      (Cisplatin/Vinorelbine). Patients will be randomized 1:1 either to the interventional study\n      group to receive 4 cycles of autologous immunotherapy with activated NK cells or to the\n      control group (BSC)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  First diagnosis of histologically and/or cytologically proven and unresectable  NSCLC\n             with clinically stage III A and III B\n\n          -  Completion of radiochemotherapy no longer than 8 weeks ago\n\n          -  Progression free according to RECIST criteria at the first assessment after\n             completion of RCTx\n\n          -  Confirmed presence of Hsp70 on patient\u00b4s tumors\n\n          -  ECOG Status(Appendices)  \u2264 2\n\n        Exclusion Criteria:\n\n          -  Any severe heart disease  or any severe concomitant disease (ECOG stage > 2)\n\n          -  NSCLC patients (stage IIIA/B) eligible for initial surgery with a confirmed consent\n             of an interdisciplinary tumorboard\n\n          -  Patients that show ALK positivity or an activating mutation of the EGFR-TK domain\n\n          -  Patients with locally advanced or metastatic non-small cell lung cancer other than\n             predominantly squamous cell histology\n\n          -  Receipt of immunosuppressive drugs including high dose systemic corticosteroids\n             within 3 weeks before study entry. Low dose corticosteroids as they are a common\n             treatment option for patients suffering from COPD are not an exclusion criterium"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118415", 
            "org_study_id": "NSCLC-TKD/IL-2", 
            "secondary_id": "2008-002130-30"
        }, 
        "intervention": {
            "arm_group_label": "Interventional", 
            "description": "Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)", 
            "intervention_name": "Hsp70-peptide TKD/IL-2 activated, autologous NK cells", 
            "intervention_type": "Other"
        }, 
        "keyword": [
            "not eligible for surgery", 
            "efficacy of immunotherapy following RCTx"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "contact": {
                "email": "Hanno.Specht@lrz.tu-muenchen.de", 
                "last_name": "Hanno Specht, Dr.", 
                "phone": "+49 (0)89 4140", 
                "phone_ext": "5910"
            }, 
            "contact_backup": {
                "email": "irina.sackerer@mri.tum.de", 
                "last_name": "Irina Sackerer, Dr.", 
                "phone": "+49 (0)89 4140", 
                "phone_ext": "4523"
            }, 
            "facility": {
                "address": {
                    "city": "Munich", 
                    "country": "Germany", 
                    "zip": "81675"
                }, 
                "name": "Klinikum rechts der Isar, Strahlentherapie und Radiologische Onkologie"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)", 
        "overall_contact": {
            "email": "hanno.specht@lrz.tu-muenchen.de", 
            "last_name": "Hanno Specht, Dr.", 
            "phone": "+49(0)89 4140 6469"
        }, 
        "overall_contact_backup": {
            "email": "gabriele.multhoff@lrz.tu-muenchen.de", 
            "last_name": "Gabriele Multhaupt, Prof.", 
            "phone": "+49(0)89 4140 4514"
        }, 
        "overall_official": {
            "affiliation": "Klinikum rechts der Isar, TU M\u00fcnchen", 
            "last_name": "Michael Molls, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progress free survival", 
            "safety_issue": "No", 
            "time_frame": "follow up after randomization for at least 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118415"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "follow up after randomization for at least 18 months"
            }, 
            {
                "measure": "toxicity (AE and SAE)", 
                "safety_issue": "Yes", 
                "time_frame": "follow up after randomization for at least 18 months"
            }, 
            {
                "measure": "quality of life (QoLQ-30, LC-13)", 
                "safety_issue": "No", 
                "time_frame": "follow up after randomization for at least 18 months"
            }, 
            {
                "measure": "biological parameters (NK cell activation)", 
                "safety_issue": "No", 
                "time_frame": "follow up after randomization for at least 18 months"
            }
        ], 
        "source": "Technische Universit\u00e4t M\u00fcnchen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Technische Universit\u00e4t M\u00fcnchen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}